Navigation Links
Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line
Date:5/25/2010

Shaanxi province.

Biostar is forecasting $2.0 million in initial Zushima sales and a $6.0 million contribution to revenues during 2011, with gross margins of 55.0%.

"We are pleased with the results of these clinical trials and are looking forward to our next stages of approval for Zushima," began Chairman and CEO Rongua Wang of Biostar Pharmaceuticals, Inc. "Our development of Zushima represents two important strategic goals for Biostar. First, Zushima highlights our commitment to develop new products to expand our product portfolio. Second, Zushima paves the way for entrance into the Chinese military market, which represents a large, new addressable market. We anticipate receiving our final approvals by September of 2010 and look forward to a successful launch of Zushima," Wang concluded.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for two patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
2. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
3. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
4. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
8. Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
(Date:9/17/2014)... A biodegradable polymer can be ... bacteria, fungi, and algae into smaller units (monomers) ... compounds, carbon dioxide, and humus in a specified ... improved costs, biodegradable polymers are proving to be ... conventional polymers. Primary factors that are responsible for ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... CHICAGO, Sept. 28, 2011 GTL Resources PLC (AIM: GTL) ... on the state of its business. Julia Henderson, the non-executive ... trends and reaffirmed the current business approach: ... with expectations and in the six month period ending September ...
... Managing RA: The Strong Woman,s Approach ... women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org. ... are two to three times more likely to develop the ... provides practical solutions and exercise advice specifically designed to ...
... delivery systems, solar cells, industrial catalysts and video displays ... possess two chemically distinct sides. These particles are named ... chemical faces allow them to form novel structures and ... of Janus particles down to a few nanometers in ...
Cached Biology Technology:The Strong Woman's Approach to Managing Rheumatoid Arthritis 2The Strong Woman's Approach to Managing Rheumatoid Arthritis 3The Strong Woman's Approach to Managing Rheumatoid Arthritis 4New technique maps twin faces of smallest Janus nanoparticles 2
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... 2014 Researchers at UTSouthwestern Medical Center have found ... apolipoprotein E, called apoE3, helps repair the lining of ... not get the benefit of this repair, putting them ... that we have identified one mechanism by which apoE3 ... variant, apoE4, is detrimental," said Dr. Philip Shaul ...
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Being social: Learning from the behavior of birds 2
... over recent years have established a foothold in understanding ... it might contribute to aging and lifespan are not ... p53 function in fruit flies show new evidence that ... against tumor formation, normal levels of p53 activity--at least ...
... be published in the January 2006 issue of Nature ... Memorial Sloan-Kettering Cancer Center have devised a novel strategy ... to genetically reverse sickle cell disease (SCD) in human ... way to genetically correct this debilitating blood disease using ...
... years, biologists have searched for evolutionary clues to this ... play in the evolution of the postreproductive lifespan? ... years, postreproductive females should contribute to the fitness of ... effect." Though many mammals, including lions and baboons, rear ...
Cached Biology News:New clues to the dark side of a key anti-tumor guardian 2Sickle cell disease corrected in human models using stem cell-based gene therapy 2Getting an evolutionary handle on life after reproduction 2
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
Biology Products: